

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Proposed Single Technology Appraisal (STA)

Vorapaxar for the secondary prevention of atherothrombotic events after myocardial infarction

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> • Merck, Sharp & Dohme (vorapaxar) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Action Heart • Afiya Trust • Anticoagulation Europe • Arrhythmia Alliance • Black Health Agency • Blood Pressure UK • British Cardiac Patients Association • Coronary Prevention Group • Cardiomyopathy Association • Different Strokes • Equalities National Council • Heart Care Partnership (UK) • HEART UK • Lifblood: The Thrombosis Charity • Muslim Council of Britain • Muslim Health Network • Network of Sikh Organisations • South Asian Health Foundation • Specialised Healthcare Alliance • Stroke Association <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Anticoagulation Specialist Association • British Association for Nursing in Cardiovascular Care • British Association for Service to the Elderly • British Atherosclerosis Society • British Association of Stroke Physicians • British Cardiovascular Intervention 	<p><u>General</u></p> <ul style="list-style-type: none"> • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British Cardiovascular Industry Association • British National Formulary • Care Quality Commission • Commissioning Support Appraisals Service • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Commercial Medicines Unit • NHS Confederation • Scottish Medicines Consortium <p><u>Possible comparator manufacturers</u></p> <ul style="list-style-type: none"> • <u>Actavis UK(clopidogrel)</u> • AstraZeneca (ticagrelor) • <u>Bristol-Myers Squibb (clopidogrel)</u> • Daiichi Sankyo (prasugrel) • Dr Reddy's laboratories (clopidogrel) • Lilly UK(prasugrel) • Sanofi (clopidogrel) • Teva UK (clopidogrel) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Antithrombotic Trialists Collaboration • British Society for Cardiovascular

Appendix C

Consultees	Commentators (no right to submit or appeal)
<p>Society (BCIS)</p> <ul style="list-style-type: none"> • British Cardiovascular Society • British Geriatrics Society • British Heart Foundation • British Society for Haematology • British Society for Haemostasis and Thrombosis • British thoracic society • British Society for Heart Failure • British Vein Institute • Clinical Leaders of Thrombosis (CLOT) • College of Emergency Medicine • National Heart Forum (UK) • Primary Care Cardiovascular Society • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • Society for Cardiological Science & Technology • Society for Vascular Nurses • Society for Vascular Technology • United Kingdom Clinical Pharmacy Association • Vascular Society <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health • NHS Birmingham Cross City CCG • NHS England • NHS Harrow CCG • Welsh Government 	<p>Research [BCS affiliated]</p> <ul style="list-style-type: none"> • Central Cardiac Audit Database • Cochrane Heart Group • Cochrane Peripheral Vascular Diseases Group • Cochrane Stroke Group • CODA • European Council for Cardiovascular Research • Health Research Authority • MRC Clinical Trials Unit • National Heart Research Fund • National Institute for Health Research • Research Institute for the Care of Older People • Wellcome Trust - Cardiovascular Research Initiative <p><u>Evidence Review Group</u></p> <ul style="list-style-type: none"> • Evidence Review Group tbc • National Institute for Health Research Health Technology Assessment Programme <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> • National Clinical Guideline Centre <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales NHS Trust

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; Healthcare Improvement Scotland ; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the *British National Formulary*).

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

¹ Non manufacturer consultees are invited to submit statements relevant to the group they are representing.